Antisense therapy for restenosis following percutaneous coronary intervention. (Q36040825)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Antisense therapy for restenosis following percutaneous coronary intervention (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Nicholas Kipshidze

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Mykola Tsapenko

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Denis Burger

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

79-89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Antigen processing for amateurs and professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Some interfaces of dendritic cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

The use of dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Origin, precursors and differentiation of mouse dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cells: immunobiology and cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Tolerogenic dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Differentiation of T regulatory cells by immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Immunology. Licence to kill

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Influence of dendritic cells on tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Active immunization against cancer with dendritic cells: the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cells resurrect antigens from dead cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Cancer immunotherapy with mRNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cell vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic cells: On the move from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Antigen presentation and T cell stimulation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Immunology: professional secrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Phagosomes are competent organelles for antigen cross-presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Fibroblasts as efficient antigen-presenting cells in lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Immune surveillance against a solid tumor fails because of immunological ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Roles of heat-shock proteins in innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

CD8+ T cell cross-priming via transfer of proteasome substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Antigen bias in T cell cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Regulation of interleukin-12 production in antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Engineered expression of the Coxsackie B and adenovirus receptor (CAR) in human dendritic cells enhances recombinant adenovirus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

CD40/CD154 interactions at the interface of tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Gene therapy of cancer with interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Functional impairment of dendritic cells caused by murine hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Modulation of tryptophan catabolism by regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Tolerance, DCs and tryptophan: much ado about IDO

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

CTLA-4-Ig regulates tryptophan catabolism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

IDO expression by dendritic cells: tolerance and tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Synergy between tumor immunotherapy and antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.1.79

21 January 2018

Identifiers

DOI

10.1517/14712598.5.1.79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15709911%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference